SCHEMBL4084773

SCHEMBL4084773

CC(C)(C)c1ccc2c(N3CCCC3)nc(Nc3ccccc3)nc2c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 9/20 0.58
MAPT P10636 5/20 0.58
KMT2A Q03164 4/20 0.58
MEN1 O00255 3/20 0.58
MAPK1 P28482 3/20 0.58
POLB P06746 2/20 0.58
RECQL P46063 2/20 0.58
ALOX15 P16050 2/20 0.58
HSD17B10 Q99714 2/20 0.58
GAA P10253 2/20 0.58
RAD52 P43351 2/20 0.58
TSHR P16473 2/20 0.58
TP53 P04637 1/20 0.58
NR4A1 P22736 1/20 0.58
HTT P42858 5/20 0.57
HPGD P15428 4/20 0.57
ALDH1A1 P00352 4/20 0.57
NPSR1 Q6W5P4 3/20 0.57
SMN1; SMN2 Q16637 3/20 0.57
TDP1 Q9NUW8 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4095460 0.88 PAK4 (0.47) LMNAMAPTKMT2AMEN1MAPK1
SCHEMBL4090388 0.85 LMNA (0.47) LMNAMAPTKMT2AMEN1MAPK1
SCHEMBL26458877 0.82 LMNA (0.80) LMNAMAPTKMT2AMEN1MAPK1
SCHEMBL4085159 0.82 KMT2A (0.49) LMNAMAPTKMT2AMEN1MAPK1
SCHEMBL4092170 0.79 HRH4 (0.45) LMNAMAPTKMT2AMEN1MAPK1
SCHEMBL4095286 0.79 MAPT (0.54) LMNAMAPTKMT2AMEN1MAPK1
SCHEMBL28374989 0.77 LMNA (0.64) LMNAMAPTKMT2AMEN1MAPK1
SCHEMBL4100471 0.76 HRH4 (0.56) KMT2AMEN1HSD17B10GAATSHR
SCHEMBL13856455 0.74 LMNA (0.97) LMNAMAPTKMT2AMEN1MAPK1
SCHEMBL1825303 0.71 LMNA (0.97) LMNAMAPTKMT2AMEN1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE CNR2, CNR1, GPR18 LMNA 2728/4885MAPT 4125/4885KMT2A 1424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.